Akinci, Baris
Meral, Rasimcan
Oral, Elif Arioglu
Article History
First Online: 8 November 2018
Compliance with Ethical Standards
:
: Baris Akinci has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis.Rasimcan Meral declares that he has no conflict of interest.Elif Arioglu Oral reports the following conflicts: Grant support: Aegerion Pharmaceuticals, Ionis Pharmaceuticals, Akcea Therapeutics, Gemphire Therapeutics (current), GI Dynamics, and AstraZeneca (the past 2 years). Consultant or advisor: AstraZeneca and BMS (Past), Thera Therapeutics, Regeneron, and Aegerion (current). Drug support: Aegerion Pharmaceuticals, Akcea Therapeutics, and Rhythm Pharmaceuticals. Other support: Boehringer Ingelheim (the past 2 years) and Aegerion Pharmaceuticals (current). She also has two patents: one patent is currently with Aegerion for the use of metreleptin for the treatment of lipodystrophy syndromes (issued and licensed, but she has not received any royalties, they go to the NIH), and the second patent is for the use of metreleptin in the treatment of NASH.
: This article does not contain any active studies with human or animal subjects performed by any of the authors.